Palatin Cash Falls to $3.7M as Quarterly Burn Triples; Going Concern Stands
PTN is trading near its 52-week low of $4.51 (14% above the low) on light trading volume (0.2× avg).
Summary
Palatin burned $3.74M of cash in the September quarter, leaving $3.74M on hand and repeating its going-concern warning, with revenue down to $361,802 from $8.85M a year ago.
Key Events · Earnings and Guidance · PTN
-
Cash Cut in Half in One Quarter
Cash and cash equivalents fell to $3,740,424 at September 30, 2026 from $7,492,014 at June 30, 2026, while current liabilities rose to $2,659,166 from $1,771,973.
-
Quarterly Operating Burn Triples
Net cash used in operating activities was $3,741,589 for the three months ended September 30, 2026, versus $1,619,382 a year earlier, driven by lower Boehringer Ingelheim receipts and higher R&D and G&A.
-
Revenue Collapses Without BI Milestones
Collaboration and license revenue was $361,802 versus $8,847,550 in the prior-year quarter, which had included the BI upfront and first research milestone; the current quarter is only R&D service reimbursement.
-
Going Concern Doubt Reiterated
Management concluded substantial doubt exists about the ability to continue as a going concern for one year from issuance, and under ASC 205-40 may not count probable future funding in that assessment.
Analysis · PTN · Life Sciences
Palatin ended September with $3.74M in cash, down from $7.49M three months earlier, after burning $3.74M of operating cash in a single quarter — roughly 2.3x the $1.62M burned in the same quarter last year. Revenue collapsed to $361,802 from $8,847,550 because the prior-year quarter captured the Boehringer Ingelheim upfront and first milestone, leaving no recurring revenue base to offset rising R&D spend on the MC4R obesity programs. Management again states substantial doubt about the ability to continue as a going concern for one year, and under ASC 205-40 it may not count future financings in that assessment. At the current burn rate the existing cash covers well under two quarters, which puts a financing — likely equity — on a short clock. The 8,755,553 potentially dilutive shares excluded from EPS (including 2,136,000 pre-funded warrants at $0.0001 and 2,765,400 Series J warrants at $6.50) mean any new raise lands on an already heavily overhung share count.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTN was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $4.51 to $31.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.